tiprankstipranks
Advertisement
Advertisement

GILD Stock Latest News

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
The FlyMerck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy
4d ago
MRK
GILD
FDA approves Gilead’s Trodelvy for two indications
PremiumThe Fly
FDA approves Gilead’s Trodelvy for two indications
5d ago
MRK
GILD
Gilead announces EC grants marketing authorization for Trodelvy
PremiumThe Fly
Gilead announces EC grants marketing authorization for Trodelvy
6d ago
GILD
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
PremiumMarket News
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
13d ago
GILD
JAZZ
Gilead announces FDA approval of sNDA for Yeztugo
PremiumThe Fly
Gilead announces FDA approval of sNDA for Yeztugo
14d ago
GILD
The Week That Was, The Week Ahead: Macro and Markets, June 14
PremiumMarket NewsThe Week That Was, The Week Ahead: Macro and Markets, June 14
15d ago
CX
KO
Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
Premium
Company Announcements
Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
17d ago
GILD
Gilead announces donation of over 2,000 vials of remdesivir to Uganda
Premium
The Fly
Gilead announces donation of over 2,000 vials of remdesivir to Uganda
17d ago
GILD
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
PremiumMarket News
RedHill Biopharma’s Opaganib Ebola Plan Gives RDHL Stock a New Catalyst
19d ago
GILD
RDHL
Buy Rating Reaffirmed on Gilead as HIV Franchise and Oncology Pipeline Offset Trodelvy EVOKE-03 Setback
PremiumRatings
Buy Rating Reaffirmed on Gilead as HIV Franchise and Oncology Pipeline Offset Trodelvy EVOKE-03 Setback
20d ago
GILD
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study
PremiumThe Fly
Merck, Gilead announce discontinuation of Phase 3 KEYNOTE-D46/EVOKE-03 study
21d ago
MRK
GILD
Gilead: Buy Rating Reiterated as Emvistegrast I&I Upside Keeps $168 Price Target Unchanged
PremiumRatings
Gilead: Buy Rating Reiterated as Emvistegrast I&I Upside Keeps $168 Price Target Unchanged
24d ago
GILD
Gilead announces launch of lenacapavir in South Africa
PremiumThe FlyGilead announces launch of lenacapavir in South Africa
24d ago
GILD
Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst
Premium
Company Announcements
Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst
25d ago
GILD
Gilead announces results from Phase 3 study of Livdelzi
Premium
The Fly
Gilead announces results from Phase 3 study of Livdelzi
27d ago
GILD
Gilead’s Lenacapavir PrEP Study: Real-World Data That Could Reshape the HIV Prevention Market
PremiumCompany Announcements
Gilead’s Lenacapavir PrEP Study: Real-World Data That Could Reshape the HIV Prevention Market
1M ago
GILD
Gilead presents new Livdelzi data at EASL congress
PremiumThe Fly
Gilead presents new Livdelzi data at EASL congress
1M ago
GILD
SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts
PremiumWeekend Updates
SM, Casey’s, Gilead, Dominion, Insulet Trending With Analysts
1M ago
D
SM
Citizens biotech analysts hold a dinnermeeting at ASCO
PremiumThe Fly
Citizens biotech analysts hold a dinnermeeting at ASCO
1M ago
AZN
LLY
FDA approves Gilead’s Hepcludex injection to treat chronic HDV infection
PremiumThe FlyFDA approves Gilead’s Hepcludex injection to treat chronic HDV infection
1M ago
GILD
Gilead receives positive CHMP opinion for Trodelvy in TNBC
Premium
The Fly
Gilead receives positive CHMP opinion for Trodelvy in TNBC
1M ago
GILD
Gilead completes acquisition of Tubulis for $3.15B upfront
Premium
The Fly
Gilead completes acquisition of Tubulis for $3.15B upfront
1M ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >